Human Serum Albumin 5%

This article discusses two clinical trials investigating the use of Human Serum Albumin 5% as part of innovative treatments for scarred vocal folds and refractory perianal Crohn’s disease fistulas. These trials aim to evaluate the effectiveness of autologous adipose-derived stromal vascular fraction (ADSVF) injections compared to a placebo containing Human Serum Albumin 5%. The studies focus on improving patient outcomes and quality of life through these novel therapeutic approaches.

Table of Contents

What is Human Serum Albumin 5%?

Human Serum Albumin 5% (HSA) is a protein-based solution derived from human blood plasma. It is a crucial component in various medical treatments and is often used in combination with other substances for therapeutic purposes[1].

Medical Uses

Human Serum Albumin 5% has several important medical applications:

  • Placebo in Clinical Trials: HSA is often used as a placebo (an inactive substance) in clinical trials to compare the effectiveness of new treatments. This helps researchers determine if a new therapy is truly beneficial[1].
  • Vehicle for Drug Delivery: It serves as a carrier for other medications, helping to distribute them effectively throughout the body[1].
  • Volume Expander: In some medical conditions, HSA can be used to increase blood volume, which is crucial for maintaining proper circulation[1].

Administration

Human Serum Albumin 5% is typically administered through the following methods:

  • Local Injection: In some treatments, HSA is injected directly into the affected area. For example, in clinical trials for vocal fold scarring and Crohn’s disease fistulas, it is injected locally[1][2].
  • Intravenous Infusion: In other cases, HSA may be given through an IV drip, especially when used as a volume expander.

The dosage and administration method can vary depending on the specific medical condition and treatment protocol.

Safety Considerations

While Human Serum Albumin 5% is generally considered safe, there are some important safety considerations:

  • Allergic Reactions: Some individuals may be sensitive to human albumin. Patients with known hypersensitivity to human albumin should not receive HSA treatments[1][2].
  • Infection Risk: As HSA is derived from human blood, there is a theoretical risk of viral transmission. However, stringent screening and purification processes are in place to minimize this risk[1].
  • Contraindications: HSA may not be suitable for individuals with certain medical conditions. Always consult with a healthcare provider before starting any new treatment[1][2].

Ongoing Research

Human Serum Albumin 5% is currently being studied in various clinical trials:

  • Vocal Fold Scarring: A study is investigating the use of HSA as part of a placebo treatment for scarred vocal folds. This research aims to compare the effectiveness of new cellular therapies against a placebo containing HSA[1].
  • Crohn’s Disease Fistulas: Another clinical trial is exploring the use of HSA as part of a placebo treatment for complex refractory perianal Crohn’s fistulas. This study compares the efficacy of cellular treatments to a placebo containing HSA[2].

These ongoing studies highlight the importance of Human Serum Albumin 5% in medical research and its potential to contribute to new treatments for various conditions.

Aspect Vocal Fold Scarring Trial Crohn’s Disease Fistula Trial
Main Objective Evaluate efficacy of ADSVF injection vs placebo on dysphonia Assess efficacy of ADSVF and microfat injection vs placebo for fistula treatment
Primary Endpoint Change in Voice Handicap Index at 6 months Clinical closure of fistula openings and MRI confirmation at 24 weeks
Key Inclusion Criteria Voice Handicap Index > 50/120, scarred vocal folds Refractory perianal Crohn’s fistula(s), CDAI ≤ 220
Key Exclusion Criteria History of malignant lesion, active infections Active luminal Crohn’s disease, recent steroid treatment
Placebo Composition Saline solution and Human Serum Albumin 5% Sodium Chloride and Human Serum Albumin 5%
Safety Considerations Monitoring of adverse events Assessment of adverse events, severity, and causal relationship

Ongoing Clinical Trials on Human Serum Albumin 5%

  • Study on the Effectiveness of Autologous Adipose-Derived Stromal Vascular Fraction Cells for Patients with Scarred Vocal Folds

    Recruiting

    2 1
    France
  • Study of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells and Microfat for Patients with Refractory Perianal Crohn’s Disease Fistulas

    Recruiting

    2 1
    Investigated diseases:
    France

Glossary

  • Autologous adipose-derived stromal vascular fraction (ADSVF): A mixture of cells obtained from a patient's own fat tissue, which contains stem cells and other regenerative cells. It is being studied for its potential healing properties in various medical conditions.
  • Human Serum Albumin 5%: A solution of human albumin protein used in medical treatments. In these trials, it is part of the placebo solution used as a control.
  • Placebo: A substance that looks like the treatment being tested but doesn't contain the active ingredient. It's used to compare the effects of the real treatment against no treatment.
  • Dysphonia: A voice disorder characterized by difficulty in speaking or an change in the sound of one's voice.
  • Perianal fistula: An abnormal connection or tunnel between the anal canal and the skin around the anus, often occurring in people with Crohn's disease.
  • Voice Handicap Index (VHI): A self-assessment tool used to measure the impact of voice disorders on a person's quality of life.
  • Crohn's Disease Activity Index (CDAI): A tool used to measure the severity of Crohn's disease symptoms and overall disease activity.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique used to create detailed images of the body's internal structures.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-adipose-derived-stromal-vascular-fraction-cells-for-patients-with-scarred-vocal-folds/
  2. http://clinicaltrials.eu/trial/study-of-autologous-adipose-tissue-derived-stromal-vascular-fraction-cells-and-microfat-for-patients-with-refractory-perianal-crohns-disease-fistulas/